Thus, concern remains for higher on-target off-tumor toxicity with greater CAR-T cell expansion, as seen in a patient treated with ERBB2-CAR-T therapy who experienced fatal cytokine release syndrome from on-target, off-tumor effect [165]. The gene discussed is ERBB2; the disease is neoplasm.